These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20840863)

  • 1. Inhibition of liver X receptor-α-dependent hepatic steatosis by isoliquiritigenin, a licorice antioxidant flavonoid, as mediated by JNK1 inhibition.
    Kim YM; Kim TH; Kim YW; Yang YM; Ryu DH; Hwang SJ; Lee JR; Kim SC; Kim SG
    Free Radic Biol Med; 2010 Dec; 49(11):1722-34. PubMed ID: 20840863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of LXRα-dependent steatosis and oxidative injury by liquiritigenin, a licorice flavonoid, as mediated with Nrf2 activation.
    Kim YW; Kim YM; Yang YM; Kay HY; Kim WD; Lee JW; Hwang SJ; Kim SG
    Antioxid Redox Signal; 2011 Mar; 14(5):733-45. PubMed ID: 20677908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones.
    Hwahng SH; Ki SH; Bae EJ; Kim HE; Kim SG
    Hepatology; 2009 Jun; 49(6):1913-25. PubMed ID: 19378344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction.
    Jin SH; Yang JH; Shin BY; Seo K; Shin SM; Cho IJ; Ki SH
    Toxicol Appl Pharmacol; 2013 Aug; 271(1):95-105. PubMed ID: 23651738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis.
    Kim YW; Kim YM; Yang YM; Kim TH; Hwang SJ; Lee JR; Kim SC; Kim SG
    Free Radic Biol Med; 2010 Feb; 48(4):567-78. PubMed ID: 20005944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ajoene, a stable garlic by-product, inhibits high fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activation.
    Han CY; Ki SH; Kim YW; Noh K; Lee DY; Kang B; Ryu JH; Jeon R; Kim EH; Hwang SJ; Kim SG
    Antioxid Redox Signal; 2011 Jan; 14(2):187-202. PubMed ID: 20560786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 20(S)-protopanaxatriol inhibits liver X receptor α-mediated expression of lipogenic genes in hepatocytes.
    Oh GS; Yoon J; Lee GG; Oh WK; Kim SW
    J Pharmacol Sci; 2015 Jun; 128(2):71-7. PubMed ID: 26109499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hexane Fraction of cyperus rotundus Prevents Non-Alcoholic Fatty Liver Disease Through the Inhibition of Liver X Receptor α-Mediated Activation of Sterol Regulatory Element Binding Protein-1c.
    Oh GS; Yoon J; Lee GG; Kwak JH; Kim SW
    Am J Chin Med; 2015; 43(3):477-94. PubMed ID: 25967664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding.
    Kay HY; Kim WD; Hwang SJ; Choi HS; Gilroy RK; Wan YJ; Kim SG
    Antioxid Redox Signal; 2011 Oct; 15(8):2135-46. PubMed ID: 21504366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic acid receptor-related orphan receptor α-induced activation of adenosine monophosphate-activated protein kinase results in attenuation of hepatic steatosis.
    Kim EJ; Yoon YS; Hong S; Son HY; Na TY; Lee MH; Kang HJ; Park J; Cho WJ; Kim SG; Koo SH; Park HG; Lee MO
    Hepatology; 2012 May; 55(5):1379-88. PubMed ID: 22183856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver.
    Sim WC; Park S; Lee KY; Je YT; Yin HQ; Choi YJ; Sung SH; Park SJ; Park HJ; Shin KJ; Lee BH
    Biochem Pharmacol; 2014 Aug; 90(4):414-24. PubMed ID: 24955981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nectandrin B, a lignan isolated from nutmeg, inhibits liver X receptor-α-induced hepatic lipogenesis through AMP-activated protein kinase activation.
    Choi du G; Kim EK; Yang JW; Song JS; Kim YM
    Pharmazie; 2015 Nov; 70(11):733-9. PubMed ID: 26790190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK.
    Kim TH; Eom JS; Lee CG; Yang YM; Lee YS; Kim SG
    Br J Pharmacol; 2013 Apr; 168(7):1647-61. PubMed ID: 23145499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.
    Lee JM; Gang GT; Kim DK; Kim YD; Koo SH; Lee CH; Choi HS
    J Biol Chem; 2014 Jan; 289(2):1079-91. PubMed ID: 24265317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes.
    Seo MS; Kim JH; Kim HJ; Chang KC; Park SW
    Toxicol Appl Pharmacol; 2015 Apr; 284(2):113-24. PubMed ID: 25737164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of honokiol and magnolol inhibits hepatic steatosis through AMPK-SREBP-1 c pathway.
    Lee JH; Jung JY; Jang EJ; Jegal KH; Moon SY; Ku SK; Kang SH; Cho IJ; Park SJ; Lee JR; Zhao RJ; Kim SC; Kim YW
    Exp Biol Med (Maywood); 2015 Apr; 240(4):508-18. PubMed ID: 25125496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGC-32 Deficiency Protects against Hepatic Steatosis by Reducing Lipogenesis.
    Cui XB; Luan JN; Chen SY
    J Biol Chem; 2015 Aug; 290(33):20387-95. PubMed ID: 26134570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMPK-mediated GSK3beta inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress.
    Choi SH; Kim YW; Kim SG
    Biochem Pharmacol; 2010 May; 79(9):1352-62. PubMed ID: 20026081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease of microRNA-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B, which is reversed by licorice flavonoid.
    Yang YM; Seo SY; Kim TH; Kim SG
    Hepatology; 2012 Dec; 56(6):2209-20. PubMed ID: 22807119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gα i/o inhibition.
    Wu HM; Yang YM; Kim SG
    Mol Pharmacol; 2011 Nov; 80(5):859-69. PubMed ID: 21803969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.